Sanofi Pasteur, the vaccines division of Sanofi, announced today that its quadrivalent influenza vaccine VaxigripTetra™ obtained a positive end of procedure from the German Reference Member State Paul Ehrlich Institute, as a conclusion of the European Decentralized Procedure. Marketing Authorizations can easily now be issued in the Reference Member State (Germany) and each of the Concerned Member States involved in this procedure. VaxigripTetra™ is a four-strain influenza vaccine, containing two A strains (A/H1N1 and A/H3N2) and two B strains (B/Victoria and B/Yamagata), for usage in people aged 3six months or older. VaxigripTetra™ is the newest addition to the Vaxigrip® family of influenza vaccines.
3D influenza/CDC
Currently, the majority of seasonal influenza vaccines are trivalent meaning that they protect versus 3 strains: two A strains and a single B strain (B/Victoria or B/Yamagata). However, two distinct influenza B strains (B/Victoria and B/Yamagata) now co-circulate international in varying and unpredictable proportions. In recent years, influenza B viruses represented about 23% of the circulating strains about the world. These proportions can easily be as higher as 90% throughout some seasons and are therefore an essential induce of influenza disease. Provided this current virological situation along with the co-flow of both B strains, influenza vaccines should be adapted and to suit along with the latest virological situation to guarantee broader degree of protection. Since trivalent influenza vaccines just contain one B strain, this co-flow makes the selection of the right strains to be included in the seasonal vaccine fairly tough to predict. As an example in Europe in 2015 92% of the documented B influenza cases were caused by the B/Victoria strain not included in the vaccine. Including the second B strain to VaxigripTetra™ will certainly handle the unpredictability issue.
“For over 60 years the expertise of Sanofi Pasteur has actually been committed to providing brand-new immunization solutions for the prevention of influenza to better protect lives and help healthcare providers satisfy the personal immunization requires of all of types of their patients. This brand-new quadrivalent influenza vaccine, which entails the 2 co-circulating B strains, completes our long line of Vaxigrip® family vaccines dedicated to fighting influenza infections and its complications. Once launched in Europe VaxigripTetra™ will offer broader protection for people from 3six months and older and support our public healthiness ambition to regularly innovate to spare lives worldwide“ said David Loew, Executive Vice President Sanofi Pasteur.
The globe healthiness Organization entails quadrivalent influenza vaccines in its recommendations, stating“Quadrivalent influenza vaccines that could potentially offer wider protection versus influenza B viruses are becoming readily available and insight must not be limited to trivalent vaccine.“
From a public healthiness perspective, using quadrivalent quite compared to trivalent influenza vaccines could have actually resulted in a further reduction of up to 1.six million influenza cases, 37,300 influenza-related hospitalizations and 14,800 influenza-related deaths in the EU over a decade.
Sanofi Pasteur supports influenza immunization policies and is committed to making vaccine solutions that suit along with the influenza epidemiology. VaxigripTetra™ is the newest formulation made by Sanofi Pasteur, offering a quadrivalent influenza vaccine. VaxigripTetra™ entails two A strains and two B strains to suggestions offer broader protection for all of age teams as of 3six months. Sanofi Pasteur intends to gradually switch all of its trivalent influenza vaccines to quadrivalent influenza vaccines worldwide.
Related:
- Flu vaccines: CDC says FluMist ‘nasal spray’ must not be used this upcoming flu season
- Norovirus: Takeda vaccine candidate in human clinical trials
- Zika vaccine: Inovio gets go ahead for starting human trials
Tags: Europe flu, flu shot, flu vaccine, H1N1, H3N2, influenza, quadrivalent influenza vaccine, Sanofi Pasteur, VaxigripTetra
from Influenza – NewsBlog http://ift.tt/28R0FwE
